Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

Phase 1

Conditions: Huntington Disease

Interventions: Drug: Placebo
Drug: CKD-504

First Posted Date: 2018-10-22

Last Posted Date: 2020-02-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 88

Registration Number: NCT03713892

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers

Phase 1

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: D578
Drug: CKD-357

First Posted Date: 2018-09-14

Last Posted Date: 2018-09-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 31

Registration Number: NCT03671941

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Pharmacokinetics and Safety Profile of CKD-333

Phase 1

Completed

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: CKD-333 formulation I
Drug: CKD-333 formulation II
Drug: CKD-330+D086

First Posted Date: 2018-09-06

Last Posted Date: 2018-10-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 37

Registration Number: NCT03659149

Locations: 🇰🇷
Seoul Saint Mary's Hospital, Seoul, Korea, Republic of

Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults

Phase 1

Conditions: Type II Diabetes

Interventions: Drug: CKD-387
Drug: D484

First Posted Date: 2018-08-24

Last Posted Date: 2018-08-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 36

Registration Number: NCT03646799

Locations: 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of

The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 Diabetes

Phase 3

Conditions: Type2 Diabetes

Interventions: Drug: Placebo
Drug: CKD-501 0.5mg

First Posted Date: 2018-08-22

Last Posted Date: 2018-08-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 240

Registration Number: NCT03641352

Locations: 🇰🇷
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 Diabetes

Phase 3

Conditions: Type2 Diabetes

Interventions: Drug: CKD-501 0.5mg
Drug: Placebo

First Posted Date: 2018-08-13

Last Posted Date: 2018-08-13

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 240

Registration Number: NCT03627182

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308

Phase 1

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: D308, CKD-501

First Posted Date: 2018-08-06

Last Posted Date: 2018-11-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 41

Registration Number: NCT03616392

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

Phase 1

Completed

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: D013, D326 and D337
Drug: D013
Drug: D326 and D337

First Posted Date: 2018-08-01

Last Posted Date: 2018-10-05

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 69

Registration Number: NCT03609606

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-380 10mg and D308 10mg

Phase 1

Conditions: Type II Diabetes Mellitus

Interventions: Drug: D308 10mg Tab.
Drug: CKD-380 10mg Tab.

First Posted Date: 2018-07-26

Last Posted Date: 2018-07-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 34

Registration Number: NCT03601910

Locations: 🇰🇷
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet

Phase 3

Completed

Conditions: Hypertensive Patients With Dyslipidemia

Interventions: Drug: CKD-330
Drug: Placebo of CKD-330
Drug: Placebo of D086
Drug: D086
Drug: Placebo of D723
Drug: D723

First Posted Date: 2018-07-12

Last Posted Date: 2019-07-24

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 154

Registration Number: NCT03583905

Locations: 🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of
🇰🇷
Catholic University Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy